Health Technology · Pharmaceuticals: Major · NSE: NECLIFE · data 2026-10-09
Nectar Lifesciences Ltd.
Health check: Weak (1.3/10 on quality, valuation vs sector, growth and momentum).
Open full analysis — chart, results, balance sheet, red flags →Key figures
Price
₹10.13
Market cap
₹204 cr
P/E
—
P/B
—
ROE
-7.5%
ROCE
-0.9%
Debt / equity
0
Dividend yield
0.00%
1-year return
-27.7%
52-week high
₹22.4
52-week low
₹9.3
Operating margin
-1171.9%
Growth
| Revenue (last 12 months) | ₹7 cr |
| Net profit (last 12 months) | ₹-245 cr |
| Sales growth, 3 years (yearly) | -90.6% |
| Profit growth, 3 years (yearly) | — |
Chart patterns
- Descending triangle — forming (key level ₹10.05)
- Head and shoulders — forming (key level ₹10.05)
Similar companies
Brooks Laboratories Limited (BROOKS) · Accretion Pharmaceuticals Ltd. (ACCPL) · Medico Remedies Ltd. (MEDICO) · Curis Lifesciences Limited (CURIS) · Bal Pharma Limited (BALPHARMA)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open NECLIFE in NSE Scanner →